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Background: Coagulation and prothrombotic potential have genuinely been associated with increased cardiovas-
cular risk. However, not all studies in this regard are conclusive. Some clinical trials have shown an increased fre-
quency of cardiovascular complications in patients receiving direct thrombin inhibitors. Previous data from
human subjects after acute cardiovascular events showed an inverse association between the thrombin genera-
tionmarker F1+2 and cardiovascular endpoints indicating that not the lowest, but a slightly elevated propensity
for thrombin generation is associated with a lower risk of cardiovascular events. This observation has been sup-
ported by ﬁndings in animal models of atherosclerosis. Hence, we evaluated the association between the endog-
enous thrombin potential (ETP) and cardiovascular death (CVD) and markers of vascular dysfunction in a large
prospective study with long-term follow up.
Method: After excluding patients receiving anticoagulants we tested ETP in 2196 participants (median follow-up
10 years) for its ability to predict vascular death (CVD). In addition, the association between ETP and sVCAM-1,
sICAM-1, LpPLA2, hsCRP and SAA was determined.
Results:We observed an inverse association between ETP and CVD with the lowest hazard ratio in the 4th ETP
quartile. The nadirs of sICAM-1 or sVCAM-1 were observed in the 3rd, for LpPLA2 in the 4th ETP quartile. Con-
versely, hsCRP and SAA were highest in the 4th quartile.
Conclusions: These results demonstrate that not the lowest ETP possible, but slightly higher levels are associated
with a reduced risk of CVD and lower markers of endothelial dysfunction, suggesting a more complex role of
thrombin in cardiovascular disease.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).s index; CI, conﬁdence intervals; CVD, cardiovascular death; DM, diabetesmellitus; ETP, endogenous thrombin potential; F1+2,
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Myocardial infarction (MI) is an acute outcome of the chronic
atherosclerotic process in large arteries. This process, whichmay remain
asymptomatic for decades, is a continuous chronic inﬂammatory
process characterized by foam cell formation and the formation of ath-
erosclerotic plaques in the vascularwall [1]. Acute events such as unsta-
ble angina, MI, or stroke subsequently result from an erosion of the
endothelium or the rupture of an established atherosclerotic plaque.
The latter processes acutely expose thrombogenic surfaces (e.g. nega-
tively charged phospholipids) and tissue factor to the circulating blood
[2], activating soluble blood coagulation factors, which trigger the for-
mation of a ﬁbrin-platelet aggregate and produce a potentially occlusive
vascular thrombus. Thus, local thrombin generation during an acute
cardiovascular event is potentially lethal. Consequently, anticoagulation
is the standard of care in acute coronary syndromes [3].
Due to its detrimental effects in the acute phase thrombin is gener-
ally perceived as a disease-promoting protease in atherogenesis. Conse-
quently, the use of new direct thrombin inhibitors has already been
discussed in this context [4]. Unexpectedly, some prospective clinical
studies evaluating new direct thrombin inhibitors for venous diseases
showed a trend to or a signiﬁcantly increased frequency of MI associat-
edwith the use of direct thrombin inhibitors [5–9]. This effect remained
signiﬁcant in two recent meta-analyses comprising 7 and 11 trials, re-
spectively, evaluating the direct thrombin inhibitor dabigatran [10,11].
While MI was not a primary endpoint in these studies, the observed in-
creased incidence rates of MI raise the question whether thrombin has
an unanticipated protective role in cardiovascular disease.
Potential beneﬁcial effects mediated by thrombin seem to be para-
dox at ﬁrst glance, but are in agreementwith results from the compara-
bly small Italian GUSTO study, which evaluated the thrombin activation
marker F1+2 in 319 consecutive patients with acute coronary syn-
dromes and a median follow-up of 29 months [12]. In this study the
risk for cardiac death or myocardial (re)infarction was lowest in pa-
tients with intermediate plasma levels of F1+2 [12]. This observation
suggests that not the lowest thrombin generation possible, but slightly
higher levels are associated with the lowest risk for cardiovascular
events, at least after a ﬁrst cardiovascular event. However, this
observation, which the authors deemed “unexpected”, has not been
conﬁrmed in a larger cohort or with a different marker so far. While
the thrombin activation marker F1+2 is a molecular marker speciﬁc
for thrombin generation in vivo, reﬂecting the acute situation, the en-
dogenous thombin potential (ETP) reﬂects the thrombin-forming ca-
pacity in a speciﬁc individual. Associations between these markers of
thrombin generation and clinical endpoints are partly discordant
[13–15], indicating that they reﬂect differential information regarding
thrombin generation.
The aim of the current study was to determine the association be-
tween the ETP and cardiovascular death (CVD) as endpoint in a large
prospective study (3156 individuals, median follow-up 10 years). In ad-
dition, we included markers of endothelial dysfunction to gain insights
into potential pathophysiological mechanisms
2. Methods
2.1. Study design and participants
We studied the participants of the Ludwigshafen Risk and Cardiovascular (LURIC)
health study, a prospective cohort study of persons undergoing coronary angiography.
The study protocol and baseline characteristics of patients have been previously published
indetail [16]. Brieﬂy, the inclusion criteriawere: German ancestry, clinical stability and the
availability of a coronary angiogram. Individuals included within the study had a status
post-acuteMI (3%, time interval betweenMI and blood sampling1 day to 4 weeks), unsta-
ble angina pectoris (26%, time interval 1 day to 4 weeks), or a history of MI (41%, time in-
terval at least 4 weeks). In patients with a status post-acute MI enrollment and blood
sampling were conducted after the patient had been transferred to a regular ward and
was clinically stable. Of those patients diagnosed as having unstable angina pectoris 62%
were troponin negative (corresponding to ~16% of the total study population), while
38% were troponin positive (corresponding to non-ST-elevation MI, ~10% of the totalstudy population). The indications for angiography in individuals in clinically stable condi-
tion (e.g. no history of MI or unstable angina pectoris, 30% of the total study population)
were a history of chest pain and/or noninvasive test results suggestive ofmyocardial ische-
mia. Individuals suffering from acute illness other than acute coronary syndromes (e.g. in-
fection, autoimmune disease, or recent accident/surgery), chronic non-cardiac diseases
(e.g. chronic renal failure, severe rheumatic arthritis), or malignancy within the past
5 years and those unable to understand the purpose of the study were excluded. The
study was approved by the ethics committee of the “Landesärztekammer Rheinland-
Pfalz” (no. 1997-203). Informed written consent was obtained from all participants.
Measurements for ETPwere complete in 3156 out of 3316 individuals. Patients receiv-
ing anticoagulants (e.g. heparinoids, vitamin K antagonists) were excluded in the current
analyses since ETP is inﬂuenced by anticoagulant treatment [17,18]. After exclusion of
patients receiving anticoagulants 2196 patients remained eligible for the current study.
Information regarding mortality (MOR) was obtained from local registries. CVD was
deﬁned as death from MI, death after an intervention to treat cardiovascular disease,
death from heart failure, or sudden cardiac death.
Diabetes mellitus was diagnosed if plasma glucose was ≥7.0 mmol/L in the fasting
state or ≥11.1 mmol/L 2 h after an oral glucose load or if individuals were receiving anti-
diabetic treatment. Hypertensionwas diagnosed if the systolic and/or diastolic blood pres-
sure exceeded 140 and/or 90 mmHg or if there was a history of hypertension, evident
through the use of antihypertensive drugs. Weight and height of all study participants
were obtained at inclusion. Information regarding smoking habits was obtained in a
standardized questionnaire [16].
2.2. Laboratory procedures
Fasting blood samples were collected before administration of any medication. The
standard laboratory methods have been described [16]. The following assays were per-
formedwith reagents fromSiemensHealthcare Diagnostics Inc., Germany: ETPwas deter-
mined using INNOVANCE ETP on a BCS coagulation analyzer and F1+2 (Prothrombin
fragment 1 + 2) was analyzed using the Enzygnost® F1+2 micro test on an automated
platform (SLT Spectra TECAN, Männedorf, Switzerland). Plasma levels of sVCAM-1 and
sICAM-1 were measured using ELISA with speciﬁc monoclonal antibodies to correspond-
ing human proteins (R&D systems GmbH, Wiesbaden, Germany) using an automated
system (Rosys Plato, Immucor, Norcross, GA, USA). LpPLA2 (lipoprotein associated phos-
pholipase A2, also referred to as platelet-activating factor acetyl-hydrolase, PAFAH) was
measured using a spectrophotometric activity assay (Azwell Auto PAF-AH kit, Azwell
Inc., Osaka, Japan) on a Hitachi 912 autoanalyzer.
2.3. Statistical analysis
All authors had access to the clinical data and results obtained. Characteristics of indi-
viduals within the four quartiles of ETP (Table 1) are presented as percentages for categor-
ical variables and asmeans (±SD) or medians (25th and 75th percentiles) for continuous
variables. Associations of categorical and continuous variables were analyzed by logistic
regression and univariate ANOVA, respectively, with covariables as indicated. All continu-
ous variables were checked for normality and skewed data were transformed logarithmi-
cally. To examine the relationship of ETPwithmortality from cardiovascular causes (CVD)
we calculated hazard ratios and 95% conﬁdence intervals (95% CI) using the Cox propor-
tional hazards model. The time to CVD variable was deﬁned as the time period between
enrollment and CVD or the time to the last follow-up (May 27, 2009) for the censored sub-
jects. We analyzed the effects of ETP on markers of endothelial dysfunction (sICAM-1,
sVCAM-1) in an Analysis of Covariance (ANCOVA) according to the general linear model
(GLM) using those factors not under examination as covariates.
Multivariable adjustment was carried out for age, gender, DM, BMI, hsCRP, vessel
score, history of smoking, hypertension, or MI, use of platelet inhibition (ASS or
Clopidogrel), ACE-inhibitors, beta blockage, statins, kidney function as well as LDL
cholesterol, HDL cholesterol, and triglycerides. The SPSS 19.0 statistical package (SPSS
Inc.) was used for all analyses. All tests were two-sided. Analyses were corrected for mul-
tiple hypotheses testing by applying theBonferroni equation to adjust the P values. Adjust-
ed P-values are reported. P b 0.05 was considered signiﬁcant.
3. Results
3.1. Intermediate levels of ETP are associatedwith a lower risk of future CVD
Clinical and biochemical characteristics of the study participants fol-
lowing stratiﬁcation ETP-quartiles are shown in Table 1. During the fol-
low-up period (median follow-up: 10 years) 345 CVDwere recorded in
the current cohort (2196 study participants). Various baseline charac-
teristics of the four groups differed signiﬁcantly (Table 1). The average
age, the prevalence rate of diabetesmellitus, and systolic blood pressure
decreased signiﬁcantly across the ETP quartiles, being lowest within the
4th ETP quartile (Table 1). However, other established or potential risk
factors for cardiovascular disease, such as the BMI, total cholesterol, LDL
cholesterol, or triglycerides were increased within the 4th ETP quartile
(Table 1). Thus, individuals in the 4th ETP quartile did not generally
Table 1
Baseline characteristics of individuals following stratiﬁcation into ETP-quartiles.
1st quartile 2nd quartile 3rd quartile 4th quartile P⁎
Number 551 545 552 548
ETP (nmol*min) 78.6 (77.5–79.5) 99.0 (98.0–99.9) 107.0 (106.0–107.9) 120.8 (119.8–121.8) b0.001
Age, years 64.7 ± 10.6 62.1 ± 10.6 61.0 ± 10.6 61.0 ± 10.1 b0.001
Male gender 392 (71.2) 383 (70.3) 368 (66.7) 347 (63.3) 0.019
BMI, kg/m2 27.0 ± 4.1 26.9 ± 3.6 27.4 ± 4.1 28.3 ± 4.0 b0.001
Myocardial infarction 0.870
One 174 181 167 183
Two or more 32 31 27 33
CAD (vessel score) 0.160
0 160 179 204 194
1 113 92 103 107
2 107 96 100 92
3 171 178 145 155
Peripheral vascular disease 57 45 44 43 0.385
Stroke/TIA 51 41 30 41 0.122
Type 2 diabetes 119 87 68 72 b0.001
HbA1c, % 6.3 ± 1.2 6.2 ± 1.17 6.2 ± 1.10 6.3 ± 1.20 0.333
Fasting glucose, mg/dl 116 ± 37 112 ± 32 111 ± 34 112 ± 35 0.139
Systolic blood pressure, mmHg 145 ± 25 143 ± 23 141 ± 23 142 ± 24 0.031
Diastolic blood pressure, mmHg 82 ± 12 82 ± 11 82 ± 11 82 ± 11 0.921
Total cholesterol, mg/dl 185 ± 34 192 ± 37 198 ± 38 210 ± 42 b0.001
LDL cholesterol, mg/dl 110 ± 99 116 ± 33 119 ± 21 129 ± 38 b0.001
HDL cholesterol, mg/dl 40 ± 10 41 ± 11 41 ± 11 40 ± 11 0.268
Triglycerides, mg/dl 162 (154–169) 164.2 (156–171) 162.2 (154–170) 182.7 (175–190) b0.001
Smoking, packyears 18.3 (16.2–20.4) 18.7 (16.7–20.8) 17.1 (15.0–19.1) 18.38 (16.3–20.4) 0.693
Therapy with beta-blocker, N 332 350 326 337 0.336
Therapy with statin, N 234 243 241 245 0.875
Therapy with ACE-inhibitor, N 292 250 243 269 0.024
Therapy with ASS, N 389 416 403 412 0.158
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between the ETP quartiles was observed regarding the history of previ-
ousMI, peripheral vascular disease, stroke or TIA (Table 1). Likewise, the
ETP quartiles did not differ in regard to the vessel score as determined
by angiography at the time of enrollment (Table 1). Use of ACE-
inhibitors differed signiﬁcantly between the ETP-quartiles, but did not
follow a constant trend across the ETP-quartiles. Medication with
beta-blockers, statins, or platelet aggregation inhibitors did not differ
between groups.
When evaluating the association between CVD and ETP we found
the highest hazard ratio (HR) for CVD in the 1st ETP quartile and signif-
icantly lower HRs for CVD in the 2nd, 3rd, and 4th ETP quartiles with an
uncorrected model approach (data not shown). After adjusting for po-
tential confounders as indicated, the HR for CVD remained highest in
the 1st ETP quartile. The HR for CVD was signiﬁcantly lower in the
2nd, 3rd, and 4th ETP quartiles, being the lowest in the 4th quartile
(HR 0.613, 95% CI 0.447–0.839, P= 0.002). Consistently, a survival anal-
ysis revealed the lowest survival rate among the individuals in the ﬁrst
ETP quartile, while survival was highest among individuals in the 4th
ETP quartile (Fig. 1). When performing analyses with data obtained
after amedian follow-up of 5 years almost identical resultswere obtain-
ed (data not shown). Taken together, among patients with pre-existing
or suspected coronary disease the risk for CVD is inversely associated
with the propensity to activate thrombin, as reﬂected by the ETP.Fig. 1. Event-free survival of individuals stratiﬁed according to ETP-quartiles. Event-free
survival is signiﬁcantly reduced in the 1st ETP-quartile compared to the 2nd, 3rd, or 4th
quartile. The P-value for the overall trend is 0.011. Data are adjusted for age, gender, dia-
betes mellitus, bodymass index, smoking, hypertension, LDL cholesterol, HDL cholesterol,
triglycerides, hsCRP, vessel score, history of myocardial infarction, and use of statins or
ACE-inhibitor.3.2. Inverse association of the ETP with markers of endothelial dysfunction
Thrombin is commonly perceived as a pro-inﬂammatory and endo-
thelial cell damaging protease. To determine whether ETP levels are pos-
itively or negatively associatedwithmarkers of endothelial cell activation
(sVCAM-1, sICAM-1) or of vascular inﬂammation (LpPLA2, lipoprotein-
associated phospholipase A2, also known as platelet-activating factor
acetylhydrolase, (PAFAH)) [19], we next evaluated the relation between
ETP and these markers of vascular disease.After correction for the confounding factors as indicated, we ob-
served an inverse association between ETP and LpPLA2 (PAFAH) with
the lowest LpPLA2 (PAFAH) levels in the 4th ETP quartile (466.8 U/l,
range 459.1–475.5, P b 0.001 for the overall trend, Fig. 2A). This distri-
bution of the vascular inﬂammationmarker LpPLA2 across ETP quartiles
resembles the inverse association between ETP and CVD. The endothe-
lial cell activation markers sICAM-1 and sVCAM-1 showed a signiﬁcant
reduction of plasma concentrations in the 2nd and 3rd ETP quartile for
both markers and in addition in the 4th ETP quartile for sVCAM-1. The
Fig. 2. Association of ETP with markers of endothelial dysfunction and inﬂammatory cell
activation. Estimated marginal means (±95% CI) of sICAM-1 (A), sVCAM-1 (B), or
LpPLA2 (C) in study participants stratiﬁed according to ETP quartiles. Data are adjusted
for age, gender, diabetes mellitus, body mass index, smoking, hypertension, LDL
cholesterol, HDL cholesterol, and triglycerides, and study participants receiving anticoag-
ulant treatment were excluded; *P b 0.05; **P b 0.01.
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Fig. 3. Association of ETP with markers of systemic inﬂammation. Estimated marginal
means (±95% CI) of hsCRP (A) and SAA (B) in study participants stratiﬁed according to
ETP quartiles. Data are adjusted for age, gender, diabetes mellitus, body mass index,
smoking, hypertension, LDL cholesterol, HDL cholesterol, and triglycerides, and study par-
ticipants receiving anticoagulant treatment were excluded; **P b 0.01.
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served in the 3rd quartile, and levels of sICAM were signiﬁcantly in-
creased in the 4th ETP quartile as compared to the 3rd quartile
(sICAM-1: 238.9 mg/l, range: 229.5–248.3; sVCAM-1: 719.7 mg/l,
range 693.5–746.0, P b 0.001 for the overall trend, Fig. 2B,C). A non-
signiﬁcant trend for increased sVCAM levels was likewise observed in
the 4th ETP quartile, indicating levels of ETP higher than those observed
in the present cohort will eventually be associated with increased
markers of endothelial cell dysfunction.
The association between CVD and systemic inﬂammation is well
established [20,21]. Therefore, we also assessed the associations between
high sensitivity c-reactive protein (hsCRP) and serum amyloid a (SAA)
and ETP. Both, hsCRP and SAA were the lowest in the ﬁrst ETP quartile
(hsCRP: 4.46 mg/l, range 3.31–5.60; SAA: 10.4 mg/l, range 3.03–17.2)
and markedly increased in higher quartiles, being signiﬁcantly elevated
in the 4th quartile (hsCRP: 10.4 mg/l, range 9.26–11.6; SAA: 35.1 mg/l,
range 27.8–42.5, P b 0.001 for the overall trend (Fig. 3A,B)).
Together, within this study, markers of endothelial cell activation
and vascular inﬂammation showed an inverse and markers of systemic
inﬂammation a positive association with ETP as the incidence of CVD
over a 10 year follow-up period.4. Discussion
The role of coagulation activation in cardiovascular disease is
being considered as detrimental in general. Trends toward a certain
hypercoagulability have been reported for subjects with diabetes,
hypertension or suffering from acute coronary events [22,23]. How-
ever, recent reports demonstrated that thrombin may not only be
disease-promoting, since it can exert endothelial protective effects
at low concentrations [24].
In the present study we have observed an inverse association of an
indicator of thrombin generation, ETP, and CVD in a large study popula-
tion (N = 2196) over a longer follow-up (10 years). While this seems
to be conﬂicting in the context, there is also other data suggesting that
elevated thrombin activation is associated with a reduced risk for CVD.
In the Italian GUSTO study a U-shaped association between the throm-
bin activation marker F1+2 and CVD or myocardial (re)infarction was
observed [12]. When using the same marker as analyzed in the GUSTO
study (F1+2) we likewise observed a U-shaped association in relation
to CVD in the current study (data not shown). The consistent results
obtained from the GUSTO and the current study imply that the inverse
or U-shaped association between cardiovascular endpoints and throm-
bin activationmarkersmay be a genuinephenomenon. The data suggest
that slightly higher levels of thrombin activation, rather than the lowest
possible, may be associated with a reduced risk for cardiovascular com-
plications and death.
The associative nature of the current study precludes any causal infer-
ence. Nonetheless, results from preclinical studies do support the notion
of the so-called “thrombin paradoxon”. The term “thrombin paradoxon”
was initially coined to describe the two-faced properties of thrombin
in regard to coagulation [25]. Thrombin has well established pro-
coagulant functions, stemming from its ability to activate platelets,
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thrombomodulin, thrombin is a potent activator of protein C (PC), an
important anti-coagulant [26]. In addition to being an anti-coagulant
activated PC (aPC) procures mechanistically distinct cytoprotective func-
tions [27], which may ameliorate the atherosclerotic process [28].
Recent studies propose that thrombin-dependent signaling itself
may convey protective effects. In that context, atherosclerosis prone
mice with genetically superimposed hypercoagulability and impaired
PC activation were shown to have increased plaque stability [29]. In
addition, low dose thrombin can mediate anti-inﬂammatory and endo-
thelial protective effects in vitro by a reduction of adhesionmolecule ex-
pression (ICAM-1, VCAM-1, E-selectin) and transendothelial migration
of leucocytes in cytokine stimulated endothelial cells [30]. Other exper-
imental studies provide further evidence for possible protective effects
of thrombin in the context of cardiovascular disease [31–34]. It is, how-
ever, noteworthy that the ETP quartiles were positively associated with
systemic markers of inﬂammation in our study. This ﬁnding suggests
that thrombin exerts its protective function primarily locally at the ves-
sel wall in a paracrine fashion.
A limitation of the current study is that blood samplingwas only per-
formed once in each patient. Althoughwe have not found an association
between ETP and acute events in our study (data not shown), ETP has
been found to be elevated in the circumstance of acute coronary events
[35], thus the distinction between acute versus chronic events may be
very important in the context of coagulation [36].
In the GUSTO study, which enrolled a lower number of patients
(N = 319), multiple blood samples were obtained during a follow-up
of 12 months. The U-shaped association between F1+2 and the primary
endpoint (cardiovascular death or myocardial (re)infarction) remained
stable during follow-up in the GUSTO study, indicating that the associa-
tion of thrombin activation markers and cardiovascular endpoints is not
an artifact caused by an acute coronary syndrome. Along this line, the
inverse association between ETP and CVD in the current study
remained stable when excluding patients with an elevated hsTNT
(larger 14 pg/ml, data not shown), supporting the notion that the in-
verse association is not an artifact related to an acute coronary event.
However, we cannot exclude the existence of other – and potentially
unrecognized – confounders contributing to the observed “thrombin
paradoxon”. In order to determine whether the current observation
can be generalized, other cohorts and populations will be required to
be studied in that speciﬁc conditions/perturbations allow further insight
into the coagulation system [37].
While the inverse association betweenmarkers of blood coagulation
activation and cardiovascular endpoints appears to be unrelated to an
acute coronary event, it cannot be generalized. In both studies (GUSTO
and LURIC) patients were selected on the basis of an index event (prov-
en or suspected acute coronary syndrome, respectively). Hence, an
“index event bias” cannot be excluded [38]. Recruitment of individuals
into a study based on an index event, such as proven or suspected
acute coronary syndrome, may skew the risk proﬁle of enrolled individ-
uals in comparison to the general population.
In the current study individuals within the 4th ETP quartile had a
lower age, a lower frequency of diabetesmellitus, and a reduced systolic
blood pressure in comparison to individuals from the 1st ETP quartile.
However, the baseline characteristics of individuals within the 4th ETP
quartile were not consistently favorable. In particular, the lipid proﬁle
was disadvantageous among individuals of the 4th ETP quartile
(increased total and LDL cholesterol and increased triglycerides).
Hence, a selection bias or “index event” effect seems less likely.
The current and previous results [12] contribute data to the ongoing
discussion regarding the efﬁcacy and safety of novel anticoagulants
(NOACs) [39]. Some [5,6,8], but not all [40,41] studies evaluating direct
thrombin inhibitors revealed a signiﬁcantly or tentatively increased
frequency of cardiovascular events. Consequently, current data is incon-
clusive on the topic [42]. However, two recentmeta-analyses conﬁrmed
that the direct thrombin inhibitor dabigatran is associated with anincreased risk of MI or acute coronary syndrome [10,11]. In contrast,
factor Xa inhibitors were consistently associated with a signiﬁcantly or
tentatively reduced frequency of cardiovascular events [8,43–46].
It is tempting to speculate that a difference in cardiovascular end-
points might indicate an unfavorable cardiovascular side effect proﬁle
of the direct thrombin inhibitors [47]. In that case the observed effect
could be a dose-dependent phenomenon and the difference in relation
to cardiovascular endpoints may not be speciﬁc for a substance, but
rather for the respective dosages employed. A dose-dependent effect
of direct thrombin inhibitors is likewise suggested by studies evaluating
the direct thrombin inhibitor hirudin in patients with acute MI. In these
studies hirudin did not only fail to show a beneﬁt, but even tended to
have a worse outcome at higher doses, prompting the authors to sug-
gest that “toomuch thrombin inhibitionmay be harmful” [3]. Regarding
NOACs the jury is still out on the case [42,47] and more clinical data are
needed. It may therefore be instructive to determine the effect of differ-
ent dosages of NOACs on cardiovascular endpoints or to deﬁne patient
populations that have speciﬁc and increased beneﬁt from such sub-
stances. Answering such questions may increase the beneﬁcial use of
NOACs.
5. Conclusion
We have provided evidence that not the lowest ETP possible, but
slightly higher levels of ETP were associated with a reduced risk of
CVD and lowermarkers of endothelial dysfunction in awell-deﬁned co-
hort of patients, suggesting a more complex role of thrombin in cardio-
vascular disease.
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